Singapore markets closed

Biora Therapeutics, Inc. (PROG)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
0.8845-0.0318 (-3.47%)
At close: 04:00PM EDT

Biora Therapeutics, Inc.

4330 La Jolla Village Drive
Suite 300
San Diego, CA 92122
United States
855 293 2639
https://www.progenity.com

Sector(s)
Industry
Full-time employees124

Key executives

NameTitlePayExercisedYear born
Mr. Eric d'EsparbesChief Financial Officer602.67kN/A1968
Mr. Aditya P. MohantyCEO & DirectorN/AN/A1967
Eric FoxVP of Fin. & Accounting & TreasurerN/AN/AN/A
Mr. Troy SeelyeChief Information OfficerN/AN/A1964
Mr. Clarke NeumannSr. VP, Gen. Counsel & Sec.N/AN/A1964
Mr. George GianakopoulosSr. VP of SalesN/AN/A1962
Ms. Robyn HattonVP of HRN/AN/AN/A
Mr. Sami Shihabi M.B.A., M.S.Chief Commercial OfficerN/AN/A1972
Mr. Kevin Howe Ph.D.Sr. VP of Strategic OperationsN/AN/AN/A
Dr. Sharat Singh Ph.D.Head of ResearchN/AN/A1959
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Progenity, Inc., a biotechnology company, provides develops and commercializes molecular testing products in the United States. The company develops targeted oral delivery of biotherapeutics, including PGN-600, an orally delivered liquid formulation of tofacitinib for the treatment of ulcerative colitis; and PGN-001, an orally delivered variant of adalimumab for the treatment of ulcerative colitis. It also develops systemic oral delivery of biotherapeutics, which include PGN-OB, a combination product of a variant of adalimumab and the Oral Biotherapeutics Delivery System (OBDM) for the treatment of inflammatory conditions; and PGN-OB2, a combination product of a GLP-1 receptor agonist and the OBDS for the treatment of Type 2 diabetes. In addition, the company develops Recoverable Sampling System, an ingestible smart capsule designed to autonomously identify locations in the GI tract, collect, and preserve a sample for analysis; and PIL Dx, an ingestible smart capsule designed to sample, measure, and transmit results. It has partnership agreement with Ionis Pharmaceuticals to evaluate the OBDS for delivery of antisense oligonucleotides. The company was formerly known as Ascendant MDX, Inc. and changed its name to Progenity, Inc. in November 2013. The company was founded in 2010 and is headquartered in San Diego, California.

Corporate governance

Biora Therapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.